Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?
Two linked parts: explain the drivers behind India's biotechnology boom, then show with concrete products and firms how that activity has benefited biopharmaceuticals.
Common trap: Answers often list biotech applications in agriculture and health. The question wants drivers (why the activity) and then biopharma outcomes: vaccines, biosimilars, affordable biologics and research services, with named examples and the remaining bottlenecks.
SyllabusAwareness in the fields of IT, Space, Computers, robotics, nano-technology, bio-technology and issues relating to intellectual property rights.
Model answer
15 marks · 250-word limitIndia set up a separate Department of Biotechnology (DBT) in 1986, among the first developing countries to do so. Three decades later, the National Biotechnology Development Strategy 2015-2020 aims to build a US$100 billion bio-industry by 2025, and biopharmaceuticals are its largest segment.
- Talent, cost advantage, disease burden
- DBT, BIRAC, biotech parks
- Startups, incubators, global partnerships
- Vaccines and biosimilars at scale
- Affordable biologics, exports
Why biotechnology activity is booming
- Institutions: DBT, the Biotechnology Industry Research Assistance Council (BIRAC, 2012), BioNEST incubators and clusters such as Hyderabad's Genome Valley and Bengaluru support research to market.
- Policy push: Startup India (2016), Make in India and 100 per cent FDI under the automatic route in greenfield pharmaceuticals attract capital.
- Talent and cost: A large pool of life-science graduates and low-cost clinical and manufacturing capability make India a hub for contract research and manufacturing.
- Global opportunity: Patent expiry of blockbuster biologics opens a large biosimilars market, while India's own burden of diabetes, cancer and infectious diseases creates demand at home.
Benefits to biopharma
- Vaccines: India supplies a large share of the world's vaccine doses; the indigenous rotavirus vaccine Rotavac entered the Universal Immunisation Programme in 2016 and won WHO prequalification in 2018.
- Biosimilars: Biocon and Mylan's trastuzumab biosimilar Ogivri became, in December 2017, the first biosimilar for breast cancer approved by the US FDA.
- Affordable biologics: Domestic recombinant insulin and monoclonal antibodies have cut prices sharply for Indian patients.
- Regulation: The 2016 Guidelines on Similar Biologics by DBT and CDSCO set a clear pathway for approval.
Mission mode and bottlenecks
- National Biopharma Mission: Approved in 2017 with Rs 1,500 crore, half of it a World Bank loan, and run by BIRAC under Innovate in India (i3), it funds biologics, vaccines, devices and shared facilities.
- Bottlenecks: Low national spending on R&D (under 1 per cent of GDP), slow and fragmented approvals and a weak academia-industry link keep India stronger in manufacturing than in discovering new biologics.
Biotechnology has made India the pharmacy of the developing world for vaccines and affordable biologics. Moving up the value chain to original discovery needs patient risk capital, faster single-window regulation and deeper university-industry research, so that the bioeconomy target becomes a health-security asset.
Read more — sources
- NCERTBiology (Class XII) — Ch. 10, Biotechnology and its Applications
- OfficialDepartment of Biotechnology, National Biotechnology Development Strategy 2015-2020
- OfficialDBT and CDSCO, Guidelines on Similar Biologics (2016)
- OfficialCabinet approval of the National Biopharma Mission (PIB, May 2017)
Related questions from earlier years
More from GS Paper 3 2018
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.